CSOP Hang Seng Biotech ETF (03174.HK) Falls 1.64%, Trades at 0.12% Discount
NewTimeSpace News: As of 13:29 on September 9, CSOP Hang Seng Biotech ETF (03174.HK) stood at HKD 3.722, down 1.64%. The ETF opened at HKD 3.758, with the latest net asset value (NAV) at HKD 3.788, a discount of 0.12%, a 52-week high of HKD 4.390, a 52-week low of HKD 2.780, a turnover of approximately HKD 1.3168 million, and assets under management of approximately HKD 965 million.
CSOP Hang Seng Biotech ETF (03174.HK) closely tracks the Hang Seng Biotech Index. The manager of the fund is CSOP Asset Management Limited. The investment objective of the Sub-Fund is to provide investment results closely tracking the performance of the Index (i.e., the Hang Seng Biotech Index) (the "Index") before deduction of fees and expenses.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSOP HS Biotech(03174.HK) +2.81%, Hengrui 9M net profit up 20.38%
- Chinese Innovative Drugs Set Record Share of ESMO Late-Breaking Abstracts; CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.81% Intraday
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.55% Intraday as Record 29 Chinese Studies Make ESMO Late-Breaker List
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 1.80% Intraday as Hansoh Signs Roche ADC Deal with US$400 Million Upfront
